Efficacy of toripalimab in combination with anlotinib in recurrent undifferentiated pleomorphic sarcoma of the sinonasal region: a case report with biomarker analysis
These findings suggest that the combination of toripalimab and anlotinib may be an effective treatment option for advanced cases of UPS in the sinonasal region.
Authors
- Hong Wang (ORCID: https://orcid.org/0000-0001-8096-873X)
- Xiaoguang Cui (ORCID: https://orcid.org/0009-0005-7689-5239)
- Rick F. Thorne (ORCID: https://orcid.org/0000-0001-7882-7081)
- Ting La (ORCID: https://orcid.org/0000-0001-6072-5722)
- Kaihong Ye
- Ying Liu (ORCID: https://orcid.org/0000-0003-1699-9309)
- Xu Dong Zhang (ORCID: https://orcid.org/0000-0001-9457-8003)
- Shun Wang (ORCID: https://orcid.org/0000-0001-5305-5134)
- Junqiao Feng
- L. L. Yan (ORCID: https://orcid.org/0000-0002-2244-4222)
- Fang Wu (ORCID: https://orcid.org/0000-0003-3639-9685)
Institutions
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-09
- DOI
- https://doi.org/10.3389/fimmu.2025.1541209
- Primary Topic
- Ear and Head Tumors
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China